← Back to Search

Panel-based pharmacogenetic genotyping for Pharmacogenetic Testing

N/A
Waitlist Available
Led By Julio Duarte, PharmD, PhD
Research Sponsored by University of Florida
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months
Awards & highlights

Study Summary

This trial will test whether panel-based pharmacogenetic testing leads to improved medication satisfaction for black and Latino patients.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in Global Patient Treatment Satisfaction Measured by the Treatment Satisfaction Questionnaire for Medication (TSQM)
Secondary outcome measures
Change in Patient Treatment Convenience Satisfaction Measured by the Treatment Satisfaction Questionnaire for Medication (TSQM)
Change in Patient Treatment Effectiveness Satisfaction Measured by the Treatment Satisfaction Questionnaire for Medication (TSQM)
Change in Patient Treatment Side Effect Satisfaction Measured by the Treatment Satisfaction Questionnaire for Medication (TSQM)

Trial Design

1Treatment groups
Experimental Treatment
Group I: Panel-based pharmacogenetic genotypingExperimental Treatment1 Intervention
All patients will receive clinical preemptive pharmacogenetic testing. Genotype results and consult notes will returned in the EHR pre-emptively. Data on implementation success metrics and PROs via patient report and TSQM measures will be collected. In addition, data on effectiveness outcomes and socioeconomic measures will be collected via the EHR and patient report, respectively.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Panel-based pharmacogenetic genotyping
2021
N/A
~100

Find a Location

Who is running the clinical trial?

National Center for Advancing Translational Science (NCATS)NIH
99 Previous Clinical Trials
36,200 Total Patients Enrolled
University of FloridaLead Sponsor
1,350 Previous Clinical Trials
719,860 Total Patients Enrolled
1 Trials studying Pharmacogenetic Testing
492 Patients Enrolled for Pharmacogenetic Testing
National Center for Advancing Translational Sciences (NCATS)NIH
324 Previous Clinical Trials
401,526 Total Patients Enrolled

Media Library

Panel-based pharmacogenetic genotyping Clinical Trial Eligibility Overview. Trial Name: NCT04630093 — N/A
Pharmacogenetic Testing Research Study Groups: Panel-based pharmacogenetic genotyping
Pharmacogenetic Testing Clinical Trial 2023: Panel-based pharmacogenetic genotyping Highlights & Side Effects. Trial Name: NCT04630093 — N/A
Panel-based pharmacogenetic genotyping 2023 Treatment Timeline for Medical Study. Trial Name: NCT04630093 — N/A
~25 spots leftby Jun 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top